focus -WSS

focus

author：entertainment 2025-09-27 19:50:10 - browse：84844

Adam's take main illustration — Molly Ferguson/STAT

Behind the stellar commercial launch of Amylyx Pharmaceuticals’ treatment for ALS lies an uncomfortable question: Does early success of the drug, called Relyvrio, make it more complicated, perhaps impossible, to pull it from the market if we find out next year that it doesn’t work?

On Monday night, Amylyx said Relyvrio sales totaled $22 million in 2022 — a period that covers slightly more than one calendar quarter given the drug’s U.S. approval last September. The company said approximately 1,300 ALS patients were on Relyvrio at the end of December, and it expects that number to at least double by the end of the first quarter.

“We’re probably going to double, closer to triple, our revenue in Q1,” said James Frates, Amylyx’s chief financial officer, speaking on Monday night’s conference call.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Texas board proposes rules on abortion law emergency exemption

explore

WSS

'Patient friction coefficient' can gauge a clinical trial's patient burden

Texas board proposes rules on abortion law emergency exemption

Pregnancy ages women, but effects reverse after delivery

Erich Jarvis studies song birds to learn about human stuttering

Readout Newsletter: Illumina, CRISPR, Regeneron

6 surprising facts about sugar

focus

focus

leisure time

Guidelines to prevent youth baseball injuries need more muscle

CRISPR technology availability, affordability needs to be expanded

After affirmative action ruling, medical educators look to 'holistic review'

Pregnancy ages women, but effects reverse after delivery

Alkermes shareholders re

Adam's Take: Intra

ChatGPT in medicine: STAT answers readers' burning questions

Pregnancy ages women, but effects reverse after delivery

As demand for Covid shots wanes, Moderna seeks its next success

Yancopoulos of Regeneron works to expand Dupixent success

focus

Readout LOUD podcast, live from the STAT Breakthrough Summit East

This gene therapy has record $4.25 million price. It's saved children.

Yancopoulos of Regeneron works to expand Dupixent success

What Kate Middleton's cancer revelation might teach the world

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

entertainment

explore

leisure time

focus